Wednesday, September 29, 2010

Glaxo Fires Latest Shot in Patent Battle with Genentech over Therapeutic Molecule Antibodies

On September 20, Glaxo Smith Kline (Glaxo) sued Genentech for infringement of US patent numbers RE40,070 and RE41,555 in the District of Delaware. The patents claim methods of purifying monomeric IgG antibody using hydrophobic interaction chromatography. GSK alleges in its complaint that Genentech's production of therapeutic monoclonal antibody products, specifically Herceptin, infringes the patents. Herceptin is an important monoclonal antibody therapeutic used to treat HER2 positive breast cancer. The complaint is available here.

The lawsuit is the latest volley in an ongoing patent war between GSK and Genentech over recombinant monoclonal antibody technology. Most of the patents that have been asserted are directed towards general methodologies used in the production and formulation of monoclonal antibody therapeutics.

For example, in 1999 Glaxo sued Genentech for allegedly infringing US patent numbers 5,545,403 and 5,545,405 (both generally claiming methods of treatment using recombinant antibody glycosylated by Chinese hamster ovary (CHO) cells), and US patent numbers 5,654,403 and 5,792,838 (both directed towards methods of stabilizing antibody formulations using copper chelators). Glaxo alleged that the patents were infringed by Genentech's production of Herceptin and Rituxan, two cancer drugs that target breast cancer whose tumors over express the HER2 protein and CD20 positive, B-cell non-Hodgkin's lymphoma, respectively. A district court held for Genentech, finding all of the asserted Glaxo claims invalid and/or not infringed. The case settled while on appeal to the Federal Circuit.

In 2000, Glaxo sued Genentech for allegedly infringing US patent number 5,633,162, which claims methods of growing CHO cells in a serum-free medium. While the complaint does not specifically identify the allegedly infringing Genentech products, Genentech reported in a filing to SEC that it assumed that the lawsuit was directed towards Herceptin and Rituxan. This case settled early in the litigation.

In 2009, Glaxo received FDA approval to market Arzerra, an anti-CD20 approved for the same indication as Genentech's Rituxan (chronic lymphocytic leukemia). Thus, the two products can be viewed as direct market competitors, perhaps biosimilars (we are still awaiting guidance from FDA as to criteria for biosimilarity under the new biosimilarity legislation passed by Congress as part of healthcare reform).

In 2009, Glaxo filed a declaratory judgment action in the Southern District of Florida seeking a judgment of invalidity, unenforceability and noninfringement with respect to Genentech's patent number 6,331,415. This patent is widely referred to as the “Cabilly II” patent, and came out of a highly publicized interference between Genentech and Celltech. The patent broadly covers the co-expression of immunoglobulin heavy and light genes in a single host cell. Genentech has been quoted as stating that the patent is "the backbone of recombinant antibody production in the biotech industry." Genentech has already asserted the patent against MedImmune and Centocor, alleging that those companies’ production of monoclonal antibodies products Synagis, ReoPro and Remicade infringe the patent. The litigation between Genentech and MedImmune resulted in a Supreme Court decision on standing of a patent licensee to bring a declaratory judgment action action challenging the patent. Genentech successfully moved to have the litigation transfer to the Central District of California, where the Centocor and MedImmune litigations are located.

In 2010, Genentech (along with Biogen Idec, its partner in the marketing of Rituxan) sued Glaxo in the Southern District of California for allegedly infringing US patent number 7,682,612. The patent claims methods of treating chronic lymphocytic leukemia using an anti-CD20 antibody, and thus invalid would appear on its face to be infringed by Arzerra. This case is somewhat noteworthy, since it is the only one in which the patent is specifically directed towards an antibody recognizing a specific antigen (CD20), as opposed to the other patents all relating to general methods of antibody production and formulation.

5 comments:

Marian said...

Antibody is one of the important particles that our body needs. And this patent can help i=us for the future use. By the way, I just want to share Creative Biolabs, I found lots of information there about antibodies technologies.

CELESTINO ARTURO said...


But Dr. Itua, Traditional Herbal Practitioner in Africa, Have cured for HIV which is extracted from some rare herbals. It is highly potential to cure AIDS 100% without any residue. Dr Itua herbal medicine has already passed various blogs on how he use his powerful herbals to heal all kind of diseases such as. Herpes, HIV,,Cushing’s disease,Heart failure,Multiple Sclerosis,Hypertension,Colo_Rectal Cancer, Diabetes, Hepatitis,Hpv,Weak ErectionLyme Disease,Blood Cancer,Alzheimer’s disease,Bechet’s disease,Crohn’s disease,Parkinson's disease,Schizophrenia,Lung Cancer,Breast Cancer,Colo-Rectal Cancer,Blood Cancer,Prostate Cancer,siva.Fatal Familial Insomnia Factor V Leiden Mutation ,Epilepsy Dupuytren's disease,Desmoplastic small-round-cell tumor Diabetes ,Coeliac disease,Creutzfeldt–Jakob disease,Cerebral Amyloid Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Scoliosis,Fibromyalgia,Fluoroquinolone Toxicity,Brain Cancer,Breast Cancer,Lung Cancer,Kidney Cancer,Syndrome Fibrodysplasia Ossificans ProgresSclerosis,Seizures,Alzheimer's disease,Adrenocortical carcinoma.Asthma,Allergic diseases.Hiv_ Aids,Herpe ,Copd,Glaucoma., Cataracts,Macular degeneration,Cardiovascular disease,Lung disease.Enlarged prostate,Osteoporosis.Alzheimer's disease,

Dementia.,Wart Remover,Cold Sore, Epilepsy, also his herbal boost immune system as well. I'm telling this because he uses his herbal medicine to cure me from hepatitis B and HIV, which i have being living for 9 months now with no side effect. The Herbal Medicine is just as good when drinking it although i have to use rest room after drinking it which I do not really care about because i just want to get the virus out of my body, I will recommend Dr Itua to anyone sick out here to contact Dr Itua with this following information.

Email...drituaherbalcenter@gmail.com /
Whatsapp Or Call...+2348149277967.
He might be late to respond because he always busy with patent, but he will surely get back to you with positive response.

alaa omran said...

https://community.ebay.com/t5/Shipping-Returns/%D8%B4%D8%B1%D9%83%D8%A7%D8%AA-%D9%86%D9%82%D9%84-%D8%B9%D9%81%D8%B4-%D9%88%D8%A7%D8%AB%D8%A7%D8%AB-%D8%A8%D8%A7%D9%84%D9%85%D9%85%D9%84%D9%83%D8%A9-%D8%A7%D9%84%D9%85%D8%AA%D8%AD%D8%AF%D8%A9/qaq-p/26768794#M143546
http://jumperads.unblog.fr/2017/03/22/%d8%a7%d9%81%d8%b6%d9%84-%d8%b4%d8%b1%d9%83%d8%a9-%d9%86%d9%82%d9%84-%d8%b9%d9%81%d8%b4-%d8%a7%d9%84%d9%82%d8%b5%d9%8a%d9%85/
http://jumperads.unblog.fr/2017/03/20/%d8%a7%d9%87%d9%85-%d8%b4%d8%b1%d9%83%d8%a7%d8%aa-%d9%86%d9%82%d9%84-%d8%a7%d9%84%d8%b9%d9%81%d8%b4-%d8%a8%d8%ae%d9%85%d9%8a%d8%b3-%d9%85%d8%b4%d9%8a%d8%b7/
http://jumperads.unblog.fr/2017/03/20/%d8%b4%d8%b1%d9%83%d8%a9-%d8%a7%d9%84%d9%85%d8%aa%d8%ad%d8%af%d8%a9-%d9%85%d9%86-%d8%a7%d9%87%d9%85-%d8%b4%d8%b1%d9%83%d8%a7%d8%aa-%d9%86%d9%82%d9%84-%d8%a7%d9%84%d8%b9%d9%81%d8%b4-%d8%a8%d9%85%d9%83/
http://jumperads.unblog.fr/2017/03/20/%d8%b4%d8%b1%d9%83%d8%a7%d8%aa-%d9%86%d9%82%d9%84-%d8%a7%d9%84%d8%a7%d8%ab%d8%a7%d8%ab-%d8%a8%d8%a7%d9%84%d8%b1%d9%8a%d8%a7%d8%b6-%d9%85%d9%88%d9%82%d8%b9-%d8%a7%d9%84%d9%85%d8%aa%d8%ad%d8%af%d8%a9/
http://jumperads.unblog.fr/2017/03/23/%d8%b4%d8%b1%d9%83%d8%a7%d8%aa-%d9%86%d9%82%d9%84-%d8%a7%d9%84%d8%b9%d9%81%d8%b4-%d8%a8%d8%ad%d8%a7%d8%a6%d9%84-2017/

alaa omran said...


شركات نقل وتنظيف
شركات نقل عفش بالطائف
شركات نقل عفش بالمدينة المنورة
شركات نقل عفش بمكة
شركات نقل عفش

alaa omran said...

شركة نقل عفش ببريدة
شركة نقل عفش بتبوك
شركة نقل عفش بالظهران
شركة نقل عفش برابغ
شركة نقل عفش بالباحه
شركة نقل عفش بعسير